Safety, outcomes and T cell characteristics in patients with relapsed or refractory MDS or CMML treated with atezolizumab in combination with guadecitabine.

Casey L O'Connell Maria R Baer Andreas Due Ørskov Sunil Kumar Saini Vu H Duong Patricia Kropf Jakob Werner Hansen Denice Tsao-Wei Hyo Sik Jang Ashkan Emadi Staffan Holmberg-Thyden Jack Bernard Cowland Brett T Brinker Kristin Horwood Ryan S Burgos Galen Hostetter Benjamin A Youngblood Sine Reker Hadrup Jean-Pierre J Issa Peter A Jones Stephen B Baylin Imran Siddiqi Kirsten Grønbaek

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Guadecitabine with atezolizumab has modest efficacy with manageable IRAEs and typical cytopenia-related safety concerns for patients with R/R MDS and CMML.

Keyphrases

acute myeloid leukemia
diffuse large b cell lymphoma
multiple myeloma
metabolic syndrome
insulin resistance
drug induced
weight loss